AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration ... 4/IL-13 inhibitor Dupixent (dupilumab ...

Dupixent (dupilumab) is a brand-name injection that’s prescribed for treating asthma. This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National Medical Products Administration (NMPA), which announced its approval the same day.

WASHINGTON, Feb 2 (Reuters) - The Trump administration over the weekend put on administrative leave dozens more staff at U.S. Agency for International Development, three sources familiar with ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

By Teddy Rosenbluth Apoorva Mandavilli and Sheryl Gay Stolberg The Trump administration, moving quickly to clamp down on health and science agencies, has canceled a string of scientific meetings ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.